Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Phase 3

Progen Pharmaceuticals